Please assess the completion status of the following clinical trial:

Trial Title: Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed adenocarcinoma of mid or low rectum~2. Locally advanced rectal cancer with one of the high-risk factors confirmed by high-resolution thin-slice Magnetic resonance image (3 mm)~   * tumors extending to within 1 mm of, or beyond the mesorectal fascia;~  * tumor extending 5 mm or more into perirectal fat;~  * resectable cT4 tumors;~  * lower third;~  * nodal involvement;~  * extramural vascular invasion~3. ECOG performance status of 0-2~4. An informed consent has been signed by the patient~Exclusion Criteria:~1. Upper rectal cancer~2. Metastatic disease~3. The patient received any previous therapy for colorectal cancer or another malignancy~4. Other malignant tumours within the last 5 years except cervical carcinoma in situ and basal cell carcinoma of the skin~5. Previous thromboembolic or haemorrhagic events within 6 months prior to registration~6. Patients with malabsorption syndrome or difficulties in swallowing~7. The patient has severe underlying diseases or poor condition to receive chemotherapy or radiotherapy~8. Pregnant of breastfeeding women~9. The patient who participate in another clinical trial, or receives any drug for the trial~10. Uncontrolled peripheral neuropathy (more than grade 2)~11. Active gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).